[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"influenza-infection\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:influenza-infection":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,49,75],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":22,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":29,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":44,"leadSponsor":46,"locationsCount":4},"100643130","expression-of-inflammatory-markers-in-the-course-of-acute-respiratory-viral-infections-100643130",false,"NCT07643688","Expression of Inflammatory Markers in the Course of Acute Respiratory Viral Infections","Expression of Inflammatory Markers in the Course of Acute Respiratory Viral Infections in Adults Aged 60 Years and Older: a Prospective Observational Study in Primary Case","AIRE-INT","Inclusion Criteria:\n\nGROUP A (Infected-Positive)\n\n* Age ≥60 years.\n* Symptoms compatible with viral respiratory infection (fever, cough, nasal congestion, dyspnea, etc.) between 24h and 72h from symptom onset.\n* Confirmed diagnosis, positive for influenza, RSV, or SARS-CoV-2 by rapid test.\n* Signed informed consent at visit 1.\n\nGROUP B (Non-Infected-Negative. Controls)\n\n* Age ≥60 years.\n* Negative diagnosis for influenza, RSV, or SARS-CoV-2 by rapid test.\n* Signed informed consent at visit 1.\n\nExclusion Criteria:\n\n* Known severe immunosuppression (e.g., transplant recipient, uncontrolled HIV).\n* Chronic immunosuppressive treatment (except low-dose corticosteroids (≤10 mg\u002F3 months)).\n* Participation in another clinical trial within the last 30 days.\n* Inability to comply with the visit schedule.\n* Immunosuppressive drugs.\n* Drugs indicated for treatment.\n* Oncology patients.\n* Terminal patients.\n* Autoimmune diseases associated with alterations in PD-L1.\n* Systemic lupus erythematosus (SLE).\n* Rheumatoid arthritis (RA).\n* Multiple sclerosis (MS).\n* Type 1 diabetes mellitus (T1DM).\n* Sjögren's syndrome.\n* Myasthenia gravis.\n* Autoimmune thyroiditis (Hashimoto's, Graves' disease).","ALL","60 Years",{"count":20,"type":21},150,"ESTIMATED","60 Days","OBSERVATIONAL","Respiratory viral infections caused by influenza, respiratory syncytial virus (RSV), and SARS-CoV-2 remain major causes of morbidity, hospitalization, and mortality among older adults worldwide. Current antiviral therapies have limited effectiveness and generally require administration within the first 48 hours after symptom onset. Increasing evidence suggests that the programmed death receptor-1\u002Fprogrammed death ligand-1 (PD-1\u002FPD-L1) immune checkpoint pathway plays an important role in the host immune response during acute viral respiratory infections. Upregulation of PD-L1 has been associated with impaired antiviral T-cell activity, immune exhaustion, and disease progression in influenza, RSV, and SARS-CoV-2 infections.\n\nThe AIRE-INT study is a prospective, observational, multicenter, non-interventional study designed to characterize the temporal kinetics of PD-L1 expression and inflammatory biomarkers in adults aged 60 years or older presenting with acute respiratory viral infection.\n\nThe study will be conducted in primary care centers and urgent care facilities within the Barcelonès Nord and Maresme healthcare regions in Catalonia, Spain. A total of 150 participants will be enrolled, including 75 with confirmed viral respiratory infection and 75 controls with negative rapid antigen tests for influenza, RSV, and SARS-CoV-2.\n\nEligible participants must be aged ≥60 years and present within 24 to 72 hours after the onset of respiratory symptoms compatible with acute viral infection, including fever, cough, nasal congestion, or dyspnea. Participants in the infected group must have a positive rapid antigen test for influenza, RSV, or SARS-CoV-2. Control participants must test negative for all three viruses. Written informed consent will be obtained before enrollment.\n\nParticipants with severe immunosuppression, chronic immunosuppressive therapy, active oncologic disease, terminal illness, or autoimmune diseases associated with PD-L1 dysregulation will be excluded.\n\nEach participant will be followed for up to 60 days and will complete two in-person study visits and one follow-up assessment.\n\nVisit 1 will occur between 24 and 72 hours after symptom onset and will include informed consent, collection of demographic and clinical data, assessment of symptoms and medical history, rapid antigen testing, and blood sample collection for PD-L1 and inflammatory biomarker analyses.\n\nVisit 2 will occur between 5 and 9 days after symptom onset and will include repeat clinical assessment and blood sample collection to evaluate temporal changes in PD-L1 expression and inflammatory responses during the acute phase of infection.\n\nVisit 3 will occur between 30 and 60 days after symptom onset and will consist of clinical follow-up through telephone contact and electronic medical record review to assess symptom resolution, complications, hospitalization, intensive care admission, and mortality.\n\nLaboratory analyses will include flow cytometry quantification of PD-L1 expression and evaluation of inflammatory biomarkers, including C-reactive protein (CRP), interleukin-6 (IL-6), tumor necrosis factor alpha (TNF-α), complete blood count parameters, renal and hepatic function markers, and virus-specific IgG antibodies. Blood samples will be processed according to standardized laboratory procedures at the Hospital Germans Trias i Pujol Microbiology Department.\n\nThe primary objective is to characterize the temporal profile of PD-L1 expression from symptom onset to infection resolution in older adults with influenza, RSV, or SARS-CoV-2 infection.\n\nSecondary objectives include:\n\nDescribing the evolution of inflammatory serum biomarkers and their association with disease severity.\n\nIdentifying biomarkers useful for screening, prognosis, and clinical monitoring.\n\nEstablishing a biological reference framework for future evaluation of PD-L1 inhibitors in respiratory viral infections.\n\nThe primary outcome measure is the level and temporal evolution of PD-L1 expression and inflammatory biomarkers between study visits. Secondary outcomes include hospitalization, intensive care admission, mortality at 60 days, symptom duration, and clinical progression.\n\nStatistical analyses will include descriptive and univariate analyses, longitudinal modeling of biomarker kinetics using locally estimated scatterplot smoothing (LOESS) and nonlinear mixed-effects regression models, and predictive logistic regression models evaluating associations between biomarkers and clinical outcomes.\n\nThe study is expected to provide important information regarding the kinetics of PD-L1 expression and inflammatory responses during acute respiratory viral infections in older adults. The findings may support the development of prognostic biomarkers and future host-directed therapeutic strategies targeting the PD-1\u002FPD-L1 pathway across multiple respiratory viruses.",[26,27,28],"SARS CoV 2 Infection","RSV Infections","Influenza Infection",[30,31,32,33,34,35,36],"SARS-CoV-2","Influenza, Human","Respiratory Syncytial Viruses","Observational Study","Programmed Cell Death 1 Receptor","Primary Health Care","Kinetics","NOT_YET_RECRUITING","2026-06-09",{"date":40,"type":41},"2026-06-11","ACTUAL",{"date":43,"type":21},"2026-07-01",{"date":45,"type":21},"2027-12",{"name":47,"class":48},"Fabiana Sherine Ganem dos Santos","OTHER",{"id":50,"slug":51,"hasResults":11,"nctId":52,"briefTitle":53,"officialTitle":53,"acronym":54,"eligibilityCriteria":55,"healthyVolunteers":56,"sex":17,"minAge":18,"maxAge":57,"enrollmentInfo":58,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":60,"conditions":61,"keywords":4,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":74},"100592808","in-depth-analysis-of-the-immune-responses-in-the-upper-respiratory-tract-in-older-adults-infected-or-colonized-with-streptococcus-pneumoniae-spn-100592808","NCT06998251","In-depth Analysis of the Immune Responses in the Upper Respiratory Tract in Older Adults Infected or Colonized With Streptococcus Pneumoniae (Spn)","NoseSpnElderly","Inclusion criteria:\n\n* Aged 60-85 years\n* Able to provide informed consent either independently or by a legal representative\n* Group 1 (Spn pneumonia patients): clinical and\u002For radiological signs of pneumonia\n* Group 1 (Spn pneumonia patients): positive Spn urinary antigen and\u002For blood culture and\u002For positive sputum test.\n* Group 2 (viral respiratory infection patients): clinical signs of a respiratory infection\n* Group 2 (viral respiratory infection patients): positive test for influenza or RSV\n* Group 3 (asymptomatic Spn-carriers): healthy without clinical signs of infection and no lower respiratory symptoms within the last month.\n\nExclusion criteria:\n\n* Immunosuppression,\n* Use of inhalation and\u002For nasal steroids the last month\n* Intubation or under invasive mechanical ventilation\n* Long-term antibiotic treatment prior to disease onset",true,"85 Years",{"count":59,"type":21},280,"The NoseSpn-Elderly study aims at characterizing the immune response in the upper respiratory tract in adults aged 60 and over diagnosed with a pneumonia due to a Streptococcus pneumoniae (Spn) infection. The immune response during the acute phase of the infection and after recovery will be compared to the immune response of asymptomatic Spn carriers as well as to the immune response of patients diagnosed with a viral respiratory infection (flu or respiratory syncytial virus (RSV)).\n\nThe primary objective of this observational study is to quantify the inflammatory response in the nasal cavity and to correlate it with bacterial\u002Fviral load and with clinical parameters. The study also aims to compare the inflammatory response measured in the nose to that measured in the blood.\n\nParticipants will have two study visits including a blood draw, several nasal samplings (nasal lining fluid and nasal cells) and a saliva sampling, one within 72 hours of their hospital admission and another one month later. Nasal lining fluid and saliva will be obtained every two or three days until discharge from the hospital or resolution of symptoms. During those visits, questions regarding symptoms will be asked.",[62,63,28],"Pneumococcal Infections","Respiratory Syncytial Virus (RSV) Infection","RECRUITING","2025-05-21",{"date":67,"type":41},"2025-05-31",{"date":69,"type":41},"2024-12-03",{"date":71,"type":21},"2026-11",{"name":73,"class":48},"University Hospital, Geneva",1,{"id":76,"slug":77,"hasResults":11,"nctId":78,"briefTitle":79,"officialTitle":79,"acronym":80,"eligibilityCriteria":81,"healthyVolunteers":11,"sex":17,"minAge":82,"maxAge":83,"enrollmentInfo":84,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":86,"conditions":87,"keywords":4,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":88,"startDateStruct":89,"completionDateStruct":91,"leadSponsor":92,"locationsCount":74},"100592809","in-depth-analysis-of-the-immune-responses-in-the-upper-respiratory-tract-of-influenza-infected-children-100592809","NCT06998264","In-depth Analysis of the Immune Responses in the Upper Respiratory Tract of Influenza-infected Children","NoseFlu-Kids","Inclusion criteria:\n\n* Aged 2-5 years\n* Presenting clinical signs of an influenza-like illness\n* Having a concomitant positive laboratory test for influenza.\n\nExclusion criteria:\n\n* Immunosuppression\n* Intubation or under invasive mechanical ventilation\n* Co-infection with RSV or SARS-CoV-2","2 Years","5 Years",{"count":85,"type":21},40,"The NoseFlu-Kids project aims at characterizing the immune response in the upper respiratory tract in children aged 2 to 5 with a laboratory-confirmed influenza infection. The immune response during the acute phase of the infection and after recovery will be compared to that of control children with no infection or vaccinated with the inactivated flu vaccine by the nasal route (recruited as part of a mirror study in Oxford).\n\nThe primary objective of this observational study is to quantify the inflammatory response in the nasal cavity and to correlate it with viral load and with clinical parameters. The study also aims to compare the inflammatory response measured in the nose to that measured in the blood.\n\nParticipants will have two study visits including a blood draw, several nasal samplings (nasal lining fluid and nasal cells) and a saliva sampling, one within 72 hours of their hospital admission and another one month later. Nasal lining fluid and saliva will be obtained every two or three days until symptoms disappear. During those visits, questions regarding symptoms will be asked.",[28],{"date":67,"type":41},{"date":90,"type":41},"2025-03-04",{"date":71,"type":21},{"name":73,"class":48}]